Sone Capital Management LLC Makes New $1.02 Million Investment in Boston Scientific Corporation $BSX

Sone Capital Management LLC bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 23,801 shares of the medical equipment provider’s stock, valued at approximately $1,016,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in BSX. FWL Investment Management LLC acquired a new stake in Boston Scientific in the 2nd quarter worth approximately $26,000. Swiss RE Ltd. bought a new stake in Boston Scientific during the fourth quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new position in Boston Scientific during the fourth quarter valued at approximately $26,000. Sfam LLC acquired a new position in Boston Scientific during the fourth quarter valued at approximately $29,000. Finally, Cresta Advisors Ltd. bought a new position in shares of Boston Scientific in the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Down 2.8%

Shares of BSX stock opened at $48.98 on Tuesday. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The firm’s fifty day simple moving average is $46.38 and its 200 day simple moving average is $57.32. The firm has a market capitalization of $70.99 billion, a P/E ratio of 19.83, a price-to-earnings-growth ratio of 1.10 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the prior year, the company earned $0.75 EPS. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has approved a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on BSX. Leerink Partners set a $60.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Wells Fargo & Company dropped their target price on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating on the stock in a report on Thursday, July 30th. BTIG Research cut their target price on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 29th. Jefferies Financial Group decreased their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, June 24th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $60.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $71.62.

Insider Activity

In related news, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.